These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 1379121

  • 21. Phase I immunotoxin trial in patients with B-cell lymphoma.
    Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D.
    Cancer Res; 1991 Aug 01; 51(15):4052-8. PubMed ID: 1855219
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G.
    Cancer Res; 1988 May 01; 48(9):2610-7. PubMed ID: 2451562
    [Abstract] [Full Text] [Related]

  • 23. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
    Weil-Hillman G, Runge W, Jansen FK, Vallera DA.
    Cancer Res; 1985 Mar 01; 45(3):1328-36. PubMed ID: 3971376
    [Abstract] [Full Text] [Related]

  • 24. Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines.
    Embleton MJ, Byers VS, Lee HM, Scannon P, Blackhall NW, Baldwin RW.
    Cancer Res; 1986 Nov 01; 46(11):5524-8. PubMed ID: 3489523
    [Abstract] [Full Text] [Related]

  • 25. [Preparation of an anti-human immunotoxin against bladder carcinoma and its in vitro targeting cytotoxicity].
    Zhao C.
    Zhonghua Zhong Liu Za Zhi; 1992 Mar 01; 14(2):109-11. PubMed ID: 1618077
    [Abstract] [Full Text] [Related]

  • 26. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
    Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Knyba RE, Wawrzynczak EJ, Blakey DC.
    Cancer Res; 1987 Nov 15; 47(22):5924-31. PubMed ID: 3499221
    [Abstract] [Full Text] [Related]

  • 27. The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats.
    Stoudemire JB, Mischak R, Foxall C, Harkonen WS, Del Rio M, Spitler LE.
    Mol Biother; 1990 Sep 15; 2(3):179-84. PubMed ID: 2222902
    [Abstract] [Full Text] [Related]

  • 28. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins.
    Manske JM, Buchsbaum DJ, Vallera DA.
    J Immunol; 1989 Mar 01; 142(5):1755-66. PubMed ID: 2465347
    [Abstract] [Full Text] [Related]

  • 29. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer.
    Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V, Ariniello P, Coral F, Ritz J.
    Int J Cancer Suppl; 1994 Mar 01; 8():57-9. PubMed ID: 7515030
    [Abstract] [Full Text] [Related]

  • 30. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
    Seon BK.
    Cancer Res; 1984 Jan 01; 44(1):259-64. PubMed ID: 6606488
    [Abstract] [Full Text] [Related]

  • 31. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T, Raso V.
    Cancer Res; 1991 Aug 15; 51(16):4316-22. PubMed ID: 1868454
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
    Wawrzynczak EJ, Cumber AJ, Henry RV, May J, Newell DR, Parnell GD, Worrell NR, Forrester JA.
    Cancer Res; 1990 Dec 01; 50(23):7519-26. PubMed ID: 2253201
    [Abstract] [Full Text] [Related]

  • 33. An immunotoxin cytotoxic for breast cancer cells in vitro.
    LeMaistre CF, Edwards DP, Krolick KA, McGuire WL.
    Cancer Res; 1987 Feb 01; 47(3):730-4. PubMed ID: 3492266
    [Abstract] [Full Text] [Related]

  • 34. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
    Ramakrishnan S, Bjorn MJ, Houston LL.
    Cancer Res; 1989 Feb 01; 49(3):613-7. PubMed ID: 2783383
    [Abstract] [Full Text] [Related]

  • 35. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.
    Grossbard ML, Fidias P, Kinsella J, O'Toole J, Lambert JM, Blattler WA, Esseltine D, Braman G, Nadler LM, Anderson KC.
    Br J Haematol; 1998 Jul 01; 102(2):509-15. PubMed ID: 9695966
    [Abstract] [Full Text] [Related]

  • 36. Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.
    Goulet AC, Goldmacher VS, Lambert JM, Baron C, Roy DC, Kouassi E.
    Blood; 1997 Sep 15; 90(6):2364-75. PubMed ID: 9310487
    [Abstract] [Full Text] [Related]

  • 37. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ, Uhr JW, Vitetta ES.
    Cancer Res; 1988 May 01; 48(9):2626-31. PubMed ID: 3258547
    [Abstract] [Full Text] [Related]

  • 38. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
    Derocq JM, Casellas P, Laurent G, Ravel S, Vidal H, Jansen F.
    J Immunol; 1988 Oct 15; 141(8):2837-43. PubMed ID: 3262669
    [Abstract] [Full Text] [Related]

  • 39. Comparison of the selective cytotoxic effects of immunotoxins containing ricin A chain or pokeweed antiviral protein and anti-Thy 1.1 monoclonal antibodies.
    Ramakrishnan S, Houston LL.
    Cancer Res; 1984 Jan 15; 44(1):201-8. PubMed ID: 6140077
    [Abstract] [Full Text] [Related]

  • 40. Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro.
    Recht LD, Griffin TW, Raso V, Salimi AR.
    Cancer Res; 1990 Oct 15; 50(20):6696-700. PubMed ID: 2208135
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.